TenderlineUK
Procurement Intelligence
Search
Find a TenderAwarded
Published 19 Feb 2024, 11:12 GMT

Official UK procurement notice

NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

Official notice

Authority: NHS England (Central government)

Framework agreement23 lotsGoodsOpen procedureSME suitable
Sectors: Medical Devices & Pharma (33) Delivery: UK
Framework ceiling (notional)£1,168,000,000total for 23 lots · framework ceiling, not attributable revenue
Submissions closed 21 Mar 2024awarded 31 May 2024
Lots 23see the lot list below
Framework period 2 yrs 10 moends 30 Apr 2027 · extension options published · starts 1 Jul 2024

Re-procurement plannedNHS National Framework for the supply and treatment of Blood Disorders · tender expected

What is being bought23 lots · detail below

Published requirement description

Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024<br/><br/>Offer reference number: CM/PHS/22/5661<br/><br/>Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months.<br/><br/>Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

CPV: Pharmaceutical products

How this framework works

From the published notice
Bids received
3 bids on the busiest of 21 lots · 9 suppliers appointed
Framework period
2 yrs 10 mo from 1 Jul 2024

Lots and requirements (23)Procurement structure

23 lots · all with a published value · same evaluation weights on every lot

Every one of these 23 lots carries the same published figure, £1: it is the framework's maximum for the whole notice, not each lot's own budget, and no share per lot is published. The cards below say ceiling above rather than repeat it.

Lot #1CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIIIAwarded 2 yrs 10 moceiling above

Standard Half-life Recombinant Factor VIII

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #2CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIIIAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #3CM/PHS/22/5661/03 EmicizumabAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/03 Emicizumab

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #4CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)Awarded 2 yrs 10 moceiling above

CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #5CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)Awarded 2 yrs 10 moceiling above

CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #6CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)Awarded 2 yrs 10 moceiling above

CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #7CM/PHS/22/5661/07 rFIX - Standard Half LifeAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/07 rFIX - Standard Half Life

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #8CM/PHS/22/5661/08 Recombinant Factor VIIAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/08 Recombinant Factor VII

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #9CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfaAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #10CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing FractionAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #11CM/PHS/22/5661/11 Factor IX - High Purity Factor IXAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/11 Factor IX - High Purity Factor IX

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #12CM/PHS/22/5661/12 Factor XAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/12 Factor X

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #13CM/PHS/22/5661/13 Factor XIII - Plasma DerivedAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/13 Factor XIII - Plasma Derived

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #14CM/PHS/22/5661/14 Factor XIII - RecombinantAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/14 Factor XIII - Recombinant

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #15CM/PHS/22/5661/15 Von willebrands factor / Factor VIIIAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/15 Von willebrands factor / Factor VIII

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #16CM/PHS/22/5661/16 Von willebrands factor - Plasma DerivedAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #17CM/PHS/22/5661/17 Von willebrands factor - RecombinantAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/17 Von willebrands factor - Recombinant

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #18CM/PHS/22/5661/18 Fibrinogen ConcentrateAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/18 Fibrinogen Concentrate

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #19CM/PHS/22/5661/19 Prothrombin Complex driedAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/19 Prothrombin Complex dried

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #20CM/PHS/22/5661/20 Protein C ConcentrateAwarded 2 yrs 10 moceiling above

CM/PHS/22/5661/20 Protein C Concentrate

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #21CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups)Awarded 2 yrs 10 moceiling above

CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #22CM/PHS/22/5661/22 Freeze Dried PlasmaCancelled 2 yrs 10 moceiling above

CM/PHS/22/5661/22 Freeze Dried Plasma

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products
Lot #23CM/PHS/22/5661/23 CaplacizumabCancelled 2 yrs 10 moceiling above

CM/PHS/22/5661/23 Caplacizumab

Contract period: 1 Jul 2024 – 30 Apr 2027 (2 yrs 10 mo)
Delivery: UK · Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Extensions: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.Variant bids: not allowed
33600000 Pharmaceutical products

What it takes to win
i

How this buyer will score bids.

The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).

Evaluation split and conditions of participation as published; the tender pack may add more
How bids were scored · same split on all 23 lots
Quality: 25%Price: 75%
Published sub-criteria (3)
  • Ease of Use: 10%
  • Security of Supply: 15%
  • price: 75%
Published award criteria (3)
  • Ease of Use: 10%
  • Security of Supply: 15%
  • Price: 75%
What this means for your bid
  • Price carries 75 of 100 points: a 10% discount moves about 7.5 points. This one is won on the number: sharpen the price before polishing the prose.
  • “NHS Framework - Blood Disorders including Haemophilia A and B - July…” is a framework: the contest is a place on its panel, not a single contract.

Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.

Procedure terms & legal framework

From the official record · publisher note attached
Procedure method
Open procedure
Legal basis
CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category
Goods
Notice status
Awarded
Procurement threshold
Unspecified in notice
Regulatory regime
Standard
Commercial structure
Framework agreement
Who may use this agreement
Not stated in the notice; call-off rights may be limited to the establishing authority
Competition type
Competitive procedure
GPA / WTO covered
Yes (GPA)
Recurring procurement
No (one-off requirement)
First published
19 Feb 2024, 11:12 GMT
Last source update
11 Jun 2024, 14:27 BST
Award evaluation window
21 Mar 2024 – …
Authority reference
CM/PHS/22/5661
FTS notice number
2024/S 000-018011
Classification (CPV)
Pharmaceutical products
Delivery area
UK
Official registry OCID
ocds-h6vhtk-043b0e Find a Tender
Contract terms
Electronic trading
e-invoicing allowed · electronic ordering · electronic payment

Publisher note: This award notice and related ITO documentation was initially advertised under the tender reference CM/PHS/22/5561, however this was a typo. <br/>Award documentation and subsequent notices reflect the correct tender reference of CM/PHS/22/5661.

How it was run

Official notice
Run through: Atamis legacy domain (health-family.force.com) · Who buys & how to bid on Atamis
Supplier login requiredLanguage: EN
Access & registration note: Legacy Salesforce domain still used in notices — use the current Atamis portal · this portal address is a legacy domain; the operator has migrated

Tender documents are also served through a separate tool: https://health-family.force.com/s/Welcome ↗

Appointment period ends
21 Mar 2024, 13:00 GMT
Submission channel
{"electronicSubmission","written"}
Accepted languages
en
Bids opened
21 Mar 2024, 13:00 GMT
Detailed submission instructions & authority contactsFrom official release

health-family.force.com/s/Welcome ↗

Timeline

21 Mar 2024 → 1 Jul 2024 · 5 dates
  1. Admission / appointment period endsperiod end, not a bid countdown
    21 Mar 2024, 13:00 GMT
  2. Bids opened
    21 Mar 2024, 13:00 GMT
  3. Notice published
    11 Jun 2024, 14:27 BST
  4. Bids must remain valid until
    19 Jun 2024, 23:59 BST
  5. Contract starts
    1 Jul 2024, 00:00 BST

Notice history

1 event · 3 releases on Find a Tender
  1. Status changed to complete
    11 Jun 2024, 14:27 BST
Published amendments (1)

This tender and related ITO documentation was initially advertised under the tender reference CM/PHS/22/5561, however this was a typo. Award documentation and subsequent notices will reflect the correct tender reference of CM/PHS/22/5661.

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast
Suppliers appointed 9admitted to the panel · see the list ↓
Bids received 31 from SMEs · busiest of 21 lots
Contracts signed 20latest 31 May 2024

31 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.

Contracts

All 20 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.

  • Standard Half-life Recombinant Factor VIII

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • rFIX - Standard Half Life

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • rFIX - Standard Half Life

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Recombinant Factor VII

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Recombinant Factor VII

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Porcine Factor VIII - susoctocog alfa

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Factor VIII Inhibitor Bypassing Fraction

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Factor IX - High Purity Factor IX

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Factor X

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Factor XIII - Plasma Derived

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Factor XIII - Recombinant

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Standard Half-life Recombinant Factor VIII

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Von willebrands factor / Factor VIII

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Von willebrands factor / Factor VIII

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Von willebrands factor - Plasma Derived

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Von willebrands factor - Recombinant

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Fibrinogen Concentrate

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Fibrinogen Concentrate

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Fibrinogen Concentrate

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

  • Prothrombin Complex dried

    Signed
    31 May 2024
    Value
    ceiling above
    Period
    … – 30 Apr 2027
    Status
    active

Bid statistics published by the authority

LotBidsSMEVCSEValid bid range
1 · CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII3bids · 3 electronic · 3 from abroad0——
2 · CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII2bids · 2 electronic · 2 from abroad1——
3 · CM/PHS/22/5661/03 Emicizumab1bids · 1 electronic · 1 from abroad0——
4 · CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)1bids · 1 electronic · 1 from abroad1——
5 · CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)1bids · 1 electronic · 1 from abroad0——
6 · CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)1bids · 1 electronic · 1 from abroad0——
7 · CM/PHS/22/5661/07 rFIX - Standard Half Life2bids · 2 electronic · 2 from abroad0——
8 · CM/PHS/22/5661/08 Recombinant Factor VII2bids · 2 electronic · 2 from abroad0——
9 · CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa1bids · 1 electronic · 1 from abroad0——
10 · CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction1bids · 1 electronic · 1 from abroad0——
11 · CM/PHS/22/5661/11 Factor IX - High Purity Factor IX1bids · 1 electronic · 1 from abroad0——
12 · CM/PHS/22/5661/12 Factor X1bids · 1 electronic · 1 from abroad0——
13 · CM/PHS/22/5661/13 Factor XIII - Plasma Derived1bids · 1 electronic · 1 from abroad0——
14 · CM/PHS/22/5661/14 Factor XIII - Recombinant1bids · 1 electronic · 1 from abroad0——
15 · CM/PHS/22/5661/15 Von willebrands factor / Factor VIII2bids · 2 electronic · 2 from abroad0——
16 · CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived1bids · 1 electronic · 1 from abroad0——
17 · CM/PHS/22/5661/17 Von willebrands factor - Recombinant1bids · 1 electronic · 1 from abroad0——
18 · CM/PHS/22/5661/18 Fibrinogen Concentrate3bids · 3 electronic · 3 from abroad0——
19 · CM/PHS/22/5661/19 Prothrombin Complex dried3bids · 3 electronic · 3 from abroad0——
20 · CM/PHS/22/5661/20 Protein C Concentrate1bids · 1 electronic · 1 from abroad0——
21 · CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups)1bids · 1 electronic · 1 from abroad0——

Contracting authority & participating public bodies

NHS England

Contracting authorityCentral GovernmentMinistry or any other national or federal authority, including their regional or local subdivisionsHealth 1st Floor, Quarry House, Quarry Hill, Leeds, Yorkshire & Humber, LS2 7UEContact name, email Published organisation website ↗

Dispute resolution & review bodies

  • The High CourtReview body London

Framework contractors & participating bidders

9 commercial parties on the notice
  • Bio Products Laboratory LtdFramework contractor07343036 Dagger Lane,, Elstree, Hertfordshire, UK, WD6 3BX
  • CSL Behring UK LtdFramework contractor01622483 4 Milton Road Haywards Heath, West Sussex, UK, RH16 1AH
  • LFBFramework contractor01118740 LFB Biopharmaceuticals Limited, Suite 104, Spirella Building, Bridge Road, Letchworth Garden City,, Hertfordshire,, UK, SG6 4ET.
  • Novo NordiskFramework contractor02372699 3 City Place. Beehive Ring Road., Gatwick. West Sussex, UK, RH6 0PA
  • Octapharma LimitedFramework contractor526209 Glassworks House, 32 Shudehill,, Manchester,, UK, M4 1EZ
  • Pfizer LtdFramework contractor100674 Walton Oaks, Dorking Road, Walton-on-the-Hill, Tadworth,, Surrey,, UK, KT20 7NS
  • Roche Products LtdFramework contractor04369760 Hexagon Place, Falcon Way, Shire Park,, Welwyn Garden City, UK, AL7 1TW
  • Sobi (Swedish Orphan Biovitrum Ltd)Framework contractor03362860 Swedish Orphan Biovitrum Ltd, Suite 2, Riverside 3, Great Abington,, Cambridgeshire., UK, CB21 6AD
  • Takeda UK LtdFramework contractor03362860 1 Kingdom Street,, London, UK, W2 6BD

Official documents & specifications (1)

Official links; attachments are not copied

Tender pack and attachments

  • Economic and financial selection criteriatenderEconomic and financial selection criteria